文献速递免疫规划传染病防控与疫情报告

发作性睡病与佐剂大流行甲型H1N1流感2009疫苗的多国评估

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment.
PubMed 文献 · Vaccine · 2018-08-16

多国动态回顾性队列和病例对照研究评估发作性睡病与AS03或MF59佐剂pH1N1疫苗的关联。除瑞典接种后发病率升高外,未发现疫苗与发作性睡病关联,但评估Pandemrix品牌疫苗的把握度有限。

要点

  • 除瑞典和台湾外,各研究点发作性睡病发病率无变化。
  • 病例对照研究未发现AS03或MF59佐剂pH1N1疫苗与发作性睡病关联。
  • 荷兰病例覆盖研究未发现Pandemrix-AS03与儿童发作性睡病关联。

核心结论

  • 除瑞典接种活动后发作性睡病发病率升高外,研究地点未发现AS03或MF59佐剂pH1N1疫苗与儿童或成人发作性睡病关联,但评估AS03佐剂Pandemrix品牌疫苗的把握度有限。

研究设计与样本

  • 使用电子健康数据库在加拿大、丹麦、西班牙、瑞典、台湾、荷兰和英国开展动态回顾性队列研究,评估pH1N1病毒流行前后及疫苗接种活动后的发作性睡病发病率。
  • 采用病例对照研究设计在阿根廷、加拿大、西班牙、瑞士、台湾和荷兰评估接种AS03和MF59佐剂pH1N1疫苗后发作性睡病风险。
  • 在荷兰还对2004年至2009年出生的儿童开展病例覆盖研究。

主要发现

  • 除瑞典和台湾外,单一研究点各时期发作性睡病发病率无变化;台湾发病率在野生型pH1N1病毒流行后升高,瑞典在pH1N1疫苗接种开始后发病率升高。
  • 病例对照研究未观察到Arepanrix-AS03或Focetria-MF59佐剂pH1N1疫苗与儿童或成人发作性睡病关联。
  • 荷兰病例覆盖研究未观察到2004年至2009年出生儿童接种Pandemrix-AS03与发作性睡病关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 评估AS03佐剂Pandemrix品牌疫苗的把握度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible association and inform policy on future use of adjuvants, we conducted a multi-country study of narcolepsy and adjuvanted pH1N1 vaccines. METHODS: We used electronic health databases to conduct a dynamic retrospective cohort study to assess narcolepsy incidence rates (IR) before and during pH1N1 virus circulation, and after pH1N1 vaccination campaigns in Canada, Denmark, Spain, Sweden, Taiwan, the Netherlands, and the United Kingdom. Using a case-control study design, we evaluated the risk of narcolepsy following AS03- and MF59-adjuvanted pH1N1 vaccines in Argentina, Canada, Spain, Switzerland, Taiwan, and the Netherlands. In the Netherlands, we also conducted a case-coverage study in children born between 2004 and 2009. RESULTS: No changes in narcolepsy IRs were observed in any periods in single study sites except Sweden and Taiwan; in Taiwan incidence increased after wild-type pH1N1 virus circulation and in Sweden (a previously identified signaling country), incidence increased after the start of pH1N1 vaccination. No association was observed for Arepanrix-AS03 or Focetria-MF59 adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the case-control study nor for children born between 2004 and 2009 in the Netherlands case-coverage study for Pandemrix-AS03. CONCLUSIONS: Other than elevated narcolepsy IRs in the period after vaccination campaigns in Sweden, we did not find an association between AS03- or MF59-adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the sites studied, although power to evaluate the AS03-adjuvanted Pandemrix brand vaccine was limited in our study.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Weibel D, Sturkenboom M, Black S, et al. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment. Vaccine. 2018. PMID: 30122647. doi:10.1016/j.vaccine.2018.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。